Concordia International is a diverse healthcare company focused on delivering its portfolio of legacy pharmaceutical products and orphan drugs to patients in more than 100 countries.
Concordia International is the result of the acquisition by Concordia Healthcare Corp (now Concordia International Corp) of the AMCo group on 21 October 2015 (). The combined businesses are highly complementary to each other, with well established product portfolios, and provide a strong platform for future growth through acquisitions in line with its strategy to build a truly global pharmaceutical company.
AMCo was created in 2013 from the merger of the Amdipharm Group with the Mercury Pharma group. After the merger, AMCo acquired global rights to Fucithalmic from LEO Pharma.
It then acquired Abcur AB to create a regional hub in the Nordics, to complement its existing direct presence in the UK, Ireland, France and Benelux. It has since opened a regional hub in Dubai for the MENA region, acquired two UK speciality pharma companies (Focus Pharmaceuticals and Primegen) and acquired Boucher & Muir Pty Limited to create a regional hub in Australia.
On 8 September 2015 AMCo announced that it was to be bought by the Canadian healthcare business Concordia Healthcare Corp (now Concordia International Corp) (). Concordia is a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs. It is publicly listed on the TSX/Nasdaq stock exchanges and is headquartered in Oakville, Toronto, Canada. The acquisition creates a leading, international pharmaceutical company, with products available in over 100 countries and operations in many of the major pharmaceutical markets in the world.
If you would like to learn more about Concordia International, its products or its people, please